
doi: 10.1007/bf02887065
pmid: 12845740
To investigate tumor angiogenesis in benign, borderline and malignant epithelial ovarian tumors and its relation with the pathogenesis of ovarian carcinoma, polycolonal antibody directed against human von Willebrand factor (factor VIII) was used to measure the microvessel density (MVD) in 66 cases (11 benign, 10 borderline, and 45 malignant) of epithelial ovarian tumors by using immunohistochemistry. The results showed that the mean MVD in epithelial ovarian cancer (31.7 +/- 11.2, 400 X) was higher than in benign and borderline tumors (16.7 +/- 6.3, 20.7 +/- 8.8 respectively, P 0.05). But there was significant difference in MVDs among those in different tumor stages (P < 0.05). MVD in stage III-IV cancer was higher than that in stage I-II (P < 0.05). It is concluded that the tumor angiogenesis is an early event in ovarian tumorgenesis. The increased tumor micovessel might be responsible for tumor development.
Adult, Ovarian Neoplasms, Neovascularization, Pathologic, Humans, Female, Middle Aged, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous
Adult, Ovarian Neoplasms, Neovascularization, Pathologic, Humans, Female, Middle Aged, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 2 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
